Christina Brzezniak, DO
Dr. Christina Brzezniak is a medical oncologist who is board-certified in Medical Oncology, Hematology, and Internal Medicine. She practices in the Reston, Virginia office of Virginia Cancer Specialists where she manages malignancies of all types, with a special interest in the use of immunotherapy for the treatment of malignant pleural mesothelioma and lung cancer.[1]
Dr. Brzezniak provides cutting-edge, compassionate care to her patients. She is also affiliated with HCA Reston Hospital and INOVA Loudoun Hospital. She is a member of the American Osteopathic Association and the American Society of Clinical Oncology.
Education and Career
Dr. Brzezniak attended the State University of New York at Buffalo and earned her medical degree from Lake Erie College of Osteopathic Medicine. She then joined the Army and completed her Internal Medicine training at Dwight David Eisenhower Army Medical Center followed by a fellowship through the John P. Murtha Cancer Center at Walter Reed National Military Medical Center.[1]
Dr. Brzezniak’s military career spans 11 years, including support of deployed troops overseas and serving as the Assistant Chief of the Hematology/Oncology Clinic at Walter Reed National Military Medical Center.
Research
Dr. Brzezniak has a long history of interest in research. While serving in the Army, she helped to build the research program at the John P. Murtha Cancer Center, and at Virginia Cancer Specialists she serves as principal investigator on multiple lung cancer trials. She is also a national clinical trials researcher and has contributed to multiple research publications on lung cancer and other types of malignancies. She is currently awaiting acceptance as a panel representative for the FDA regarding the elimination of barriers to the management of lung cancer.[1]
Her notable publications include:[2]
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer Daniel Morgensztern, Michal G. Rose, Saiama N. Waqar, John C. Morris, Patrick C. Ma, Thomas J. Reid, Christina Brzezniak, Karen Zeman, Arvinda Padmanabhan, Jo Ann Hirt…>; British Journal of Cancer. 2019 Jul 30
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. Michelle A. Ojemuyiwa, Karen Zeman, Alexander I. Spira, Bryan Oronsky, Carolyn M. Ray, Jane B. Trepel, Min-Jung Lee, Ifeyinwa Onyiuke, Christina Brzezniak>; Clinical Case Reports. 2018 Nov 5
A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. Christina Brzezniak, Bryan Oronsky, Rahul Aggarwal>; European Urology. 2018 Feb 1
